You have reached the maximum number of Guideline views for today. By creating a free account, you can increase your number of complimentary daily views.
To view this Guideline, please log in to your account. If you do not have an account, you can create one for free by clicking the button below.
Hormone therapy (HT) in Women with Gynecologic Cancers and in Women at High Risk for Developing a Gynecologic Cancer
Publication Date: May 1, 2020
Last Updated: March 14, 2022
Recommendations
Having trouble viewing table?
Hormone Therapy in Gynecologic Cancer Survivors
Uterine cancer
Early stage endometrial cancer
HT acceptable
Advanced stage endometrial cancer
HT not recommended
Uterine sarcoma
HT not recommended
Ovarian cancer
High grade serous ovarian cancer
HT acceptable
Low grade serous and endometrioid ovarian cancer
HT not recommended
Cervical cancer
HT acceptable
Hormone Therapy in Women at High Risk for Developing Gynecologic Cancer
BRCA mutation with no personal history of breast cancer
HT acceptable
BRCA mutation with personal history of breast cancer
HT not recommended
Lynch syndrome
HT acceptable
Overview
Title
Hormone therapy (HT) in Women with Gynecologic Cancers and in Women at High Risk for Developing a Gynecologic Cancer